Paul Koller

Trials

Studies that name Paul Koller as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:35 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT07914166 · Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  City of Hope Medical Center · not yet recruiting · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · principal investigator
• Ph1
  NCT06454409 · Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

  City of Hope Medical Center · suspended · Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Leadership, Planning and Evaluation
  P30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2004 to 2026
  Named on NCT07914166, NCT06454409